Thread by @MunkThePunk

Diclazuril - Golden Opportunity!

#SeQuent receives CEP approval for Diclazuril API.

Diclazuril is used for prevention of Coccidiosis in livestock. Coccidiosis is a parasitic disease of the intestinal tract of animals caused by coccidian protozoa.

The disease spreads from one animal to another by contact with infected feces or ingestion of infected tissue. Diarrhea, which may become bloody in severe cases, is the primary symptom.

Diclazuril is an antiprotozoal drug and is a preferred drug of choice for treating coccidiosis in livestock due to zero-day withdrawal period. It is also used in horses to treat equine protozoal myeloencephalitis caused by Sarcocystis neurona.

What is not mentioned in the article that informed about CEP approval of Diclazuril for SeQuent is that it is also used for Broilers, Turkey’s, chickens, rabbits and guinea pigs for fattening them to prevent this disease.

The biggest trigger lately is the Bird Flu in Europe and around the world. Due to culling of the whole farms and all livestock, the owners and the linked companies have to get new livestock and grow them quickly to bring their business back.

This applies to all sorts of livestock. Diclazuril is not only anti-coccidiosis but is also a growth promoter as it helps in fattening of livestock. Hence, there will be a wider use of Diclazuril across all livestock farms that got affected by BirdFlu.

And guess what! Sequent/Alivira is the second company in the world to receive approval for Diclazuril from the European Directorate for the Quality of Medicines (EDQM). The product was also recently commercialised in the US with supplies to the innovator.

This is Alivira’s 11th CEP approval from the EDQM. SeQuent is the only listed player in India that supplies this API to the regulated market.